Search research articles
Contact Us
Filters
Showing results (21-30 of 39) with videos related to
Page
of 4
Sort By:
Genes, Chromosomes & Cancer
|
May 24, 2023
The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next-generation sequencing
Melanie A Jones, Kirsten M Timms, Shanell Hatcher, et al.
The Journal of Molecular Diagnostics : JMD
|
October 3, 2022
Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort: Validation of Decentralized Genomic Profiling
Carsten Denkert, Marcel Romey, Brad Swedlund, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2019
Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and <i>BRCA1/2</i> Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis
Melinda L Telli, Charles Chu, Sunil S Badve, et al.
British Journal of Cancer
|
October 25, 2018
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Darren R Hodgson, Brian A Dougherty, Zhongwu Lai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2010
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer
Bryan T J Hennessy, Kirsten M Timms, Mark S Carey, et al.
Investigational New Drugs
|
January 10, 2018
A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer
Diane A J van der Biessen, Jourik A Gietema, Maja J A de Jonge, et al.
Gynecologic Oncology
|
February 10, 2021
Clinical significance of homologous recombination deficiency score testing in endometrial Cancer
Jean H Siedel, Kari L Ring, Wei Hu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2015
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
Steven J Isakoff, Erica L Mayer, Lei He, et al.
Genome Medicine
|
December 19, 2024
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib
Alan Barnicle, Isabelle Ray-Coquard, Etienne Rouleau, et al.
American Journal of Human Genetics
|
May 13, 2008
Genome-wide association scan identifies a prostaglandin-endoperoxide synthase 2 variant involved in risk of knee osteoarthritis
Ana M Valdes, John Loughlin, Kirsten M Timms, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 39) with videos related to
Sort By:
Page
of 4
Genes, Chromosomes & Cancer
|
May 24, 2023
The landscape of BRCA1 and BRCA2 large rearrangements in an international cohort of over 20 000 ovarian tumors identified using next-generation sequencing
Melanie A Jones, Kirsten M Timms, Shanell Hatcher, et al.
The Journal of Molecular Diagnostics : JMD
|
October 3, 2022
Homologous Recombination Deficiency as an Ovarian Cancer Biomarker in a Real-World Cohort: Validation of Decentralized Genomic Profiling
Carsten Denkert, Marcel Romey, Brad Swedlund, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 5, 2019
Association of Tumor-Infiltrating Lymphocytes with Homologous Recombination Deficiency and <i>BRCA1/2</i> Status in Patients with Early Triple-Negative Breast Cancer: A Pooled Analysis
Melinda L Telli, Charles Chu, Sunil S Badve, et al.
British Journal of Cancer
|
October 25, 2018
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Darren R Hodgson, Brian A Dougherty, Zhongwu Lai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2010
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer
Bryan T J Hennessy, Kirsten M Timms, Mark S Carey, et al.
Investigational New Drugs
|
January 10, 2018
A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer
Diane A J van der Biessen, Jourik A Gietema, Maja J A de Jonge, et al.
Gynecologic Oncology
|
February 10, 2021
Clinical significance of homologous recombination deficiency score testing in endometrial Cancer
Jean H Siedel, Kari L Ring, Wei Hu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 8, 2015
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
Steven J Isakoff, Erica L Mayer, Lei He, et al.
Genome Medicine
|
December 19, 2024
Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib
Alan Barnicle, Isabelle Ray-Coquard, Etienne Rouleau, et al.
American Journal of Human Genetics
|
May 13, 2008
Genome-wide association scan identifies a prostaglandin-endoperoxide synthase 2 variant involved in risk of knee osteoarthritis
Ana M Valdes, John Loughlin, Kirsten M Timms, et al.
Page
of 4